First and only once-daily triple therapy in a single inhaler for adult patients with COPD or ASTHMA


Do you have an adult patient with COPD or ASTHMA who may benefit from TRELEGY? Review clinical trials to learn more.

Savings on TRELEGY
TRELEGY has broad coverage

Broad coverage:
% of commercially insured patients† .
% of Medicare Part D patients† .
Individual access may vary by geography and plan benefit design.
*“Covered” is defined as any potential for reimbursement from a health plan and may include step edits, prior authorizations, and other restrictions. Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety.
†“Patients” means covered lives for all commercial and employer payer types (excluding Managed Medicaid), and covered lives enrolled in Medicare payer types as calculated by MMIT as of .
Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives for this geography.
Source: Managed Markets Insight & Technology, LLC (MMIT), database as of .
What is the safety profile of TRELEGY?
See reported common adverse
reactions from clinical trials.
Helpful resources for you and your patients
Find practice support tools, useful downloads, and videos about triple therapy with TRELEGY.
See patient profile for COPD.